Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

NCT07662018 · clinicaltrials.gov ↗

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Prospective Observational Study
Gemcitabine
Docetaxel
Melphalan
Carboplatin
Stem Cell Transplantation
Pediatric Relapsed
Refractory Germ

Interventions

DRUG: Gemcitabine (GEM)
DRUG: Docetaxel
DRUG: Melphalan
DRUG: Carboplatin

Sponsor

M.D. Anderson Cancer Center